The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. We asked, How to select maintenance therapies post-autologous stem cell transplant (ASCT) for patients with high-risk MM? In this expert discussion, Shaji Kumar and Naresh Bumma provide their insights into post-ASCT maintenance therapy for high-risk patients. The experts consider the use of lenalidomide as a monotherapy versus in combination with a proteosome inhibitor, whilst sharing their thoughts on the challenges in defining the high-risk population. Kumar and Bumma present their individual management strategies for this patient population and examine existing clinical data, highlighting the need for prospective trials. This discussion concludes with a look to the future management of high-risk multiple myeloma post-ASCT. Hosted on Acast. See acast.com/privacy for more information.